Microfluidic systems redefined biology by providing platforms that handle small fluid volumes, catalyzing advancements in cellular and molecular studies.
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Clive Svendsen, Meritxell Huch, Ameen Salahudeen, and Maksim Plikus will discuss the latest advances in using patient-derived stem cells to create more accurate disease models.